Re: Still waiting for that BETonMACE CKD sub-study 7 months later

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BKC

Rank: Treasurer [?]

Points: 599 [?]

Votes: 19 Score: 4.1 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Still waiting for that BETonMACE CKD sub-study 7 months later

in response to

Re: Still waiting for that BETonMACE CKD sub-study 7 months later

fouremm

posted on Jun 13, 2020 04:43PM

Hi Fouremm,

As much as I would have liked to consider other possibilities, I think the title of the slide answers the questions: "Limitations of the CKD study".

There was no difference over time in eGFR in CKD patients.

That said, "difference", when uttered by a scientist does not necessarily carry the same meaning as when used in every day language. "Differences" for scientists tend to be statistically significant, thus there may have been a trend, but it was just not statistically signficant.

If there was absolutely no difference, it a bit surprising that Resverlogix (according to the fact sheet) has planned a trial aimed at looking improvements in renal function in low eGFR patients. They may have seen a sign/trend/glimmer of hope supporting an eGFR improvement claim, but that kind of detail is not something retail investors are privy to.

Tundup, if you are reading this, I understand that you felt the information you received some time ago on eGFR data was misleading, but can you add a bit more in terms of circumstances of the information you received - some hypotheses on why you heard what you heard?

Best regards,

BKC

3 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply